History

Pacific Edge was formed in February 2001 with the goal of developing simple-to-use, non-invasive, highly accurate diagnostic and prognostic tools for cancer. The early years of the company were focused on research and development from which to create a product pipeline. In addition, the company has been vigilant regarding formal protection of intellectual property to underpin the value of the products developed. As a result of a successful development programme, Pacific Edge currently has a pipeline of products for the early detection and management of targeted cancers. The first of these products, Cxbladder^®, was launched in the New Zealand and Australian markets in 2010.

• 2001 Pacific Edge founded based on exclusive licenses from the University of Otago
• 2002 Listed on the New Zealand Stock Exchange (NZX)
• 2005 Cxbladder^® patent filed
• 2008 Cxbladder^® clinical trial initiated
• 2010 Cxbladder^® offered as a commercial service